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Chronic obstructive lung disease determines morbidity and mortality of patients with cystic fibrosis (CF). CF airways are
characterized by a nonresolving neutrophilic inflammation. After pathogen contact or prolonged activation, neutrophils release
DNA fibres decorated with antimicrobial proteins, forming neutrophil extracellular traps (NETs). NETs have been described to
act in a beneficial way for innate host defense by bactericidal, fungicidal, and virucidal actions. On the other hand, excessive
NET formation has been linked to the pathogenesis of autoinflammatory and autoimmune disease conditions. We quantified free
DNA structures characteristic of NETs in airway fluids of CF patients and a mouse model with CF-like lung disease. Free DNA
levels correlated with airflow obstruction, fungal colonization, and CXC chemokine levels in CF patients and CF-like mice. When
viewed in combination, our results demonstrate that neutrophilic inflammation in CF airways is associated with abundant free
DNA characteristic for NETosis, and suggest that free DNA may be implicated in lung function decline in patients with CF.
1. Introduction
Cystic fibrosis (CF) is a fatal disorder characterized by
chronic and progressive lung disease that determines mor-
bidity and mortality of these patients [1]. Airways of CF
patients show a chronic nonresolving neutrophilic inflamma-
tion, which increases upon infection and disease progression.
Neutrophil products, such as elastase, chitinase-like proteins
and chemokines, have been identified as important risk
factors of lung damage and lung function decline and are
suggested as biomarkers based on both cross-sectional and
longitudinal studies in patients with CF [2–7] and mice
with CF-like lung disease [8]. Previous studies also provided
evidence that free extracellular DNA is highly increased
in CF airway specimen [9], initially referred to as DNA
derived from necrotic cells. However, several studies have
now established that CF airway secretions contain meshwork
structures reminiscent of NETs [10–14].
Neutrophils represent the first line of cellular host defense
against bacteria and fungi. Traditionally, neutrophils have
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been known to combat pathogens intracellularly by phago-
cytosis, a paradigm that was extended and challenged by the
finding that neutrophils can immobilize and kill pathogens
extracellularly through NET formation (NETosis) [15, 16].
These released NETs consist of a nuclear DNA backbone
equipped with characteristic granule and cytoplasmic pro-
teins. While NETosis has been initially described as a novel
form of cell death [17], recent studies demonstrated that
also living neutrophils, eosinophils, and basophils can form
extracellular traps (ETs) by expelling their mitochondrial
DNA [18–23]. Viable/nonlytic rapid NET formation has been
further found in response to Staphylococcus aureus infection,
where phagocytosis, chemotaxis, andNET formationworked
in a collaborative manner [24, 25].
In this study, we investigated CF airway inflammation
with a focus on the abundance of free DNA structures
characteristic for NETs in different airway specimen (sputum
and BAL) obtained from patients with CF and 𝛽ENaC-
transgenic (𝛽ENaC-Tg) mice with CF-like lung disease [26–
28] and correlated DNA levels with proinflammatory CXC
chemokines, characteristic CF pathogens, andmeasurements
of lung function. Our results demonstrate that free airway
DNA levels correlate with obstructive lung disease and
proinflammatory chemokines in CF patients and CF mice
and could serve as therapeutic target and potential biomarker
in CF lung disease.
2. Methods
2.1. NET Characterization. NETs were visualized and char-
acterized by staining of extracellular DNA, citrullinated
histones, myeloperoxidase, or elastase. The quantification of
free DNA was performed using the Quant-iT PicoGreen
assay (Molecular Probes, Inc., Eugene, OR, USA) based
on a green fluorescent dye that binds DNA. For CLSM,
samples were collected with poly-D-lysine-precoated cover
slides placed on freshly harvested human sputum and were
left in place for 5–10min in order to adhere. The cover slides
were washed in PBS at pH 7.4 and transferred into a fixative
of 4% paraformaldehyde for 2 hours. The fixed samples
were washed with PBS, permeabilized (0.5% Triton X-100 in
PBS), and blocked (10% normal goat serum, 10mM glycine
in diluent containing 0.5% bovine serum albumin, 0.5%
normal goat serum, and 0.5% Triton X-100 in PBS). DNA
was stained with DAPI (Sigma-Aldrich, Vienna, Austria). For
visualisation of citrullinated histones, the samples were incu-
bated with the rabbit anti-human citrullinated histone H3
antibody (ab77164, Abcam, Cambridge, UK). This antibody
was detected in CLSM by means of a secondary anti-rabbit
FITC antibody (ab6717, Abcam, Cambridge, UK). For visual-
isation of neutrophil elastase ormyeloperoxidase, the samples
were incubated with rabbit antineutrophil elastase (ab21595,
Abcam, Cambridge, UK) or mouse antimyeloperoxidase
(ab25989, Abcam, Cambridge, UK) antibodies. Negative
controls were initially incubated in 500 U/mLDNase (DNase
I recombinant, grade I, Roche Diagnostics GmbH, Vienna,
Austria) for 20min at room temperature (RT) and then
stoppedwith 50mMEDTA in excess and thereafter treated as
mentioned above.The specimens were analysed with a CLSM
(Zeiss LSM 510meta UV, Carl Zeiss GmbH, Vienna, Austria).
Cross talk between different channels was avoided by using
multitracking modus. Relative fluorescence was quantified
using Zeiss LSM software application. For scanning electron
microscopy (SEM) studies, sputum samples, collected as
described above, were fixed for two hours with Karnovsky
fixative. The fixed samples were washed with 0.1M sodium
cacodylate at pH7.6 and blocked in 1% BSA for 20min at RT.
Then, samples were dehydrated in ascending series of ethyl
alcohol, critical-point-dried, and subsequently sputteredwith
gold. The specimens were examined in a scanning electron
microscope ESEM XL30 (FEI Company, PHILIPS, Eind-
hoven, Netherlands) operating at 20 kV.Thenegative controls
were digested with DNase and thereafter processed in the
same way. For transmission electron microscopy (TEM)
studies, sputum samples were collected with formvar-coated
grids placed on freshly harvested sputum and left in place for
60 sec in order to adhere. The grids were then immediately
transferred into a fixative of 4% paraformaldehyde in PBS
at pH 7.4 for two hours. The fixed samples were washed
with PBS, permeabilized, and blocked (10% normal goat
serum, 10mM glycine, 0.2% Tween 20 in diluent containing
0.5% bovine serum albumin, and 0.5% Triton X-100 in PBS).
For visualisation of citrullinated histone H3, the grids were
incubated with rabbit anti-human citrullinated histone H3
(citrulline 2 + 8 + 17) antibody [CitH3] (ab77164, Abcam,
Cambridge, UK) and a gold-conjugated secondary antibody
(ab27237, Abcam, Cambridge, UK, gold sphere diameter
20 nm or ab27235, Abcam, Cambridge, UK, for 5 nm gold
sphere diameter). Finally, the grids were stained with 1%
uranyl acetate (Sigma-Aldrich, Vienna, Austria).Thenegative
controls were digested with DNase and thereafter processed
in the same way. A second type of negative controls was
obtained by omitting the primary antibody. For ultrathin
sputum sections, sputum samples were stained with the
ruthenium-red-osmium-tetroxide technique to enable the
visualization of NETs and bacterial glycocalyx. Briefly, the
samples were fixed with 1.2% glutaraldehyde (buffered at pH
6.5 with 0.1M sodium cacodylate) with the addition of 0.05%
ruthenium-red for 2 hours at RT. Postfixation was performed
with 1% osmium-tetroxide (buffered at pH 6.5 with 0.1M
sodium cacodylate) and 0.05% ruthenium-red for 2 h at RT.
The specimens were routinely embedded in Epon 812. Ultra-
thin sections were examined with a transmission electron
microscope LEO EM 910 (LEO Elektronenmikroskopie Ltd.,
Oberkochen, Germany).
2.2. Quantification of CXCR2 Ligands. Levels of human or
murine CXCR2 ligands were quantified by commercial sand-
wich ELISA kits according to the manufacturer’s instructions
as previously described [29].
2.3. Human Subjects. CF patients and healthy control sub-
jects were included in the study (Table 1). The diagnosis of
CF was based on typical clinical symptoms and positive
sweat tests or disease-causing mutations in the CFTR gene.
Inclusion criteria for CF patients were stable concomitant
therapy at least two weeks prior to the study and a forced
expiratory volume in 1 second (FEV
1
) > 25% of predicted
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Table 1: Patient characteristics.
Cystic fibrosis Healthy controls
Number total 80 10
Age (years) 22 ± 10 28 ± 8
Gender (M : F) 48/32 6/4
FEV1 (% pred) 64.6 ± 15 n.d.
FVC (% of pred) 73 ± 20 n.d.
MEF
25–75 (% pred) 33 ± 12 n.d.
Neutrophils (%) in sputum 88 ± 29 20 ± 9
dF508 homozygous/
heterozygous/other 38/27/15 n.d.
Statistical analysis was performed with ANOVA and the two-sided t-test. M:
male, F: female; FEV1: forced expiratory volume in 1 second (% of predicted);
results are expressed as means ± standard deviation; n.d. not determined.
value. Ten control subjects without pulmonary diseases were
selected as the control group. These subjects had no pul-
monary disease and were free of respiratory tract infections.
Chronic bacterial and fungal colonization were diagnosed
using the Leeds criteria [30], if the organism was present in
more than 50%of patient samples in the year prior to analysis.
Bacterial and fungal species were analyzed using culture-
based methods. The study was approved by the Institutional
Review Board and by the Ethics Committees of the Medical
Faculty, Ludwig-Maximilians University, Munich, and the
University of Tübingen, Germany. Written informed consent
was obtained from all patients and control subjects prior to
the study. This study was conducted in accordance with the
amended Declaration of Helsinki.
2.4. CFAirway Specimen. Induced sputumwas obtained after
inhalation of 5.85% hypertonic sodium chloride for 15min.
Low-speed (4∘C, 500 g for 10min) supernatants obtained
from induced sputumwere further centrifuged at 4∘C, 4000 g
for 20min. Cell-free sputum supernatant was stored at −80∘C
until analysis. Bronchoscopy and BAL (4× 1mL of 0.9%NaCl
per kg body weight) were performed as described previously
[31, 32]. Because of the high percentage of neutrophils the first
fraction of BAL was used for subsequent analyses.
2.5. Experimental Animals. All animal studies were approved
by the Regierungspräsidium Karlsruhe or Munich, Germany.
The generation of 𝛽ENaC-Tg mice (line 6608) has been
previously described [26]. The colony was maintained on a
mixed genetic background (C3H/HeN × C57BL/6N), and
𝛽ENaC-Tg mice were identified by PCR. Wild-type litter-
mates served as controls in all experiments.Micewere housed
in a pathogen-free animal facility and had free access to chow
and water.
2.6. Bronchoalveolar Lavage and Cytokine Measurements.
For bronchoalveolar lavage (BAL), mice were deeply anes-
thetized via intraperitoneal injection of a combination of
ketamine/xylazine (120mg/kg and 16mg/kg, resp.), the tra-
chea was cannulated, and lungs were carefully lavaged
twice with 800𝜇L PBS. KC and MIP2 concentrations were
measured in BAL supernatant using ELISA according to
manufacturer’s instructions and total cell counts were deter-
mined and differential cell counts performed on cytospin
preparations. Studies were performed by investigators who
were blinded with respect to the genotype and the treatment
of the mice.
2.7. Pulmonary Function Studies in Mice. We used inva-
sive pulmonary function devices (Forced Maneuver System,
Buxco Research Systems, Wilmington, NC). Mouse pul-
monary function testing was performed and analyzed as
published previously [33]. Allmicewere anesthetizedwith i.p.
MMF (medetomidine, midazolam, and fentanyl), intubated,
and placed in a forced pulmonary maneuver system. In
a heated plethysmograph chamber, mice were ventilated
at an average rate of 140 breaths per minute, and flow,
mouth, esophageal pressure and heart rate were monitored
to measure forced expiratory volume at 100ms (FEV100).
2.8. Statistical Analysis. Comparisons among all groups were
performed with ANOVA and comparisons between two
patient groups were performed with the two-sided 𝑡-test.
Correlation analysis was performed by calculating the two-
tailed Pearson correlation coefficient. Statistical analysis was
performed with Prism 4.0 (GraphPad Software) and STATA
version 8.2 for Windows (STATA Corporation).
3. Results
Increased extracellular DNA fibres with morphological NET
characteristics were found in airway specimen from CF
patients (Figures 1(a) and 1(b)). Positive costaining for
neutrophil elastase (Figure 1(a)) and citrullinated histones
(Figures 1(a), 1(b), and 1(d)), as characteristic NET markers,
and negative staining for F-actin (Figure 1(d)) supported the
notion that the CF airway DNA fibres represented NETs
rather than necrosis-derived DNA. Treatment of CF airway
fluids with DNase dissolved these DNA-NET-like structures
further confirming their nature as DNA strands (data not
shown). Ultrastructural imaging methods supported these
findings and revealed a complex meshwork of DNA strands
with bacteria entangled (Figure 1(b)). Free DNA was present
in different CF airway compartments, in particular in sputum
(Figure 1(a)), bronchoalveolar lavage fluid (BAL) (Figure 1(c),
lower panel), and lung tissue (Figure 1(c) upper panel).
Remarkably,most abundant freeDNAwas found inCF sputa,
whereas in BAL and lung tissue, lower amounts of free DNA
strands were detected, which is consistent with the observa-
tion that neutrophilic inflammation is most prominent in the
proximal/bronchial airway compartments in CF lung disease.
In BAL fluid, we observed lower amounts of DNA NET-
like structures, but observed that elastase was associated to
free DNA structures and also appeared to colocalize with
the neutrophil’s cellular membrane (Figure 1(c), lower panel).
In CF airway fluids, we found DNA/NET-like structures
associated with bacteria (Figure 1(e)). However, associations
of free DNA structures with both live and dead bacteria were
noted (Figure 1(e)).








Figure 1: Free NET-like DNA structures in CF lung disease. (a) Immunological characterization of free DNA structures in CF airway fluids
by CLSM. Upper two panel rows: NET-like DNA structures in induced CF sputum. Blue: DAPI stains DNA-NET backbone. Red: elastase.
Lower two panel rows: Blue: DAPI, red: citrullinated histones. Scale bar: 20𝜇m. (b) Ultrastructure of free NET-like DNA structures. Upper
and middle panels: SEM images of CF airway fluids. Arrow marks bacteria entrapped in DNA-NET-like structures. Scale bar: 2𝜇m; Middle
right panel: TEM staining of citrullinated histones in CF airway fluids (sputa). Lower panel: Ultrathin sections of CF airway DNA-NET-
like structures. The NETs and the bacterial extracellular polysaccharides are visualized by the ruthenium-red-osmium-tetroxide technique.
Bacteria embedded in a dense wickerwork of NETs. Arrowheads mark NETs; asterisk: bacterial extracellular polysaccharide. (c)Upper panel:
free DNA structures in CF lung tissue. Red: MPO (as characteristic NET component). Blue: DAPI (DNA). Inlays mark characteristic NET-
areas. Lower panel: CF airway NETs in CF BAL fluids. Red: elastase (as characteristic NET component). Blue: DAPI (DNA). (d) Costainings
of DAPI, citrullinated histones, and F-actin. Scale bar: 20 𝜇m. (e) Dead/live staining of CF airway fluids (induced sputum). Free DNA and
dead bacteria appear red; vital bacteria appear green.
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Stratifying CF patients for disease severity, we found that
CF patients with poor pulmonary function had higher levels
of free DNA in their airway fluids than patients with mild
lung disease (Figure 2(a)). We further found that the airway
free DNA levels were associated with fungal colonization
with Aspergillus fumigatus but surprisingly not with bacterial
infection (Figure 2(a)). Representative NET-DNA (DAPI)
staining of CF patient groups stratified for lung disease sever-
ity is shown in Figure 2(b).Highly increased levels of theCXC
chemokines CXCL1 (GRO-alpha), CXCL2 (GRO-beta), and
CXCL8 (IL-8)were detected inCF airway fluids (Figure 2(c)).
Since CXCR1 is proteolytically cleaved on CF airway neu-
trophils [4, 32], CXCR2 remains the main binding site
for these chemokines in the CF airway microenvironment.
CF airway NETs correlated positively with levels of the
proinflammatory chemokine CXCL2 (Figure 2(d)). These
findings provide evidence that CF lung disease features free
airwayDNA levels characteristic forNETosis and suggest that
increased free DNA levels are associated with poor lung
function of CF patients.
To investigate the role of free DNA/NET formation in
vivo, we used transgenic mice with airway-specific overex-
pression of the amiloride-sensitive epithelial Na+ channel
(𝛽ENaC-Tg) as amodel of CF-like lung disease [26, 27].These
mice phenocopy airway surface liquid depletion, mucociliary
dysfunction, and chronic airway disease with neutrophilic
airway inflammation,mucus obstruction, and structural lung
damage [26, 27, 34]. Similar to human CF airway fluids,
levels of the CXCR2 ligands CXCL1 and CXCL2 (Figure 3(a))
and free DNA (Figure 3(b)) were highly increased in the
BAL airway fluids of 𝛽ENaC-Tg mice compared to wild-type
controls. Also consistent with the data obtained from human
CF lung disease samples, the extent of free DNA in murine
CF airway fluids correlated positively with the levels of the
CXCR2 ligand CXCL2 (Figure 3(c)) and with pulmonary
obstruction parameters (FEV100) (Figure 3(d)), whereas no
correlationwas found between free DNA and levels of CXCL1
or parameters of pulmonary restriction parameters (data not
shown).
4. Discussion
NETosis is regarded as a double-edged sword in human
disease: on one hand, NETs can capture, immobilize, and kill
pathogens; on the other hand, uncontrolled and infection-
independent NET formation has the potential to harm host
tissue through histones [35], proteases, or other mechanisms
[21, 36, 37]. Related to the latter mechanism, NET formation
has recently been implicated in the pathogenesis of autoin-
flammatory and autoimmune disease conditions, such as
lupus, preeclampsia, septic shock, and autoimmune vasculitis
[36–40]. Beyond these conditions, NETs were found, in
concert with platelets andmonocytes, to play a role in throm-
bus formation and deep vein thrombosis [41, 42]. However,
antihost defense and autoinflammatory conditions are not
dichotomous in their nature and temporarily overlap upon
resolution of infection or progression into chronic infec-
tion, especially in immunocompromised conditions. Viewing
these findings in combination, the balance between targeted
antimicrobial host defense and nontargeted tissue damage
of NET is delicate, but it is essential for the understanding
and therapeutic potential ofNET formation in humandisease
conditions.
The potential role of NETs in inflammatory lung diseases
has just begun to evolve [40]. Several studies have now pro-
vided evidence for NETosis or NETosis-like structures in CF
lung disease and broadened the potential role of NET forma-
tion in the complex pathogenesis of infective CF lung disease
[43]. We and others have demonstrated previously that free
DNA NET-like structures are abundantly detectable in CF
airway secretions [10–14]. Recently, a further study found that
CF sputum showed NETosis characteristics and implicated
macrophage migration-inhibitory factor (MIF) in the forma-
tion of NETs in the context of CF lung disease [12]. Here, we
confirm and extend these previous observations by showing
that CF airway free DNA levels correlate with pulmonary
obstruction in CF patients and mice. These observations
are reasonable, given the continuous and nonresolving neu-
trophil recruitment and activation within CF airways, being
supported by the beneficial effect of recombinant inhaled
DNase (Dornase alpha) in CF patients with the strongest
evidence in moderate and severe disease severity [44–46].
Based on the increasing extent of neutrophilic inflammation
and pulmonary obstruction, the evidence of free NET-like
DNA structures in CF airways tempts us to speculate that in
earlier and milder stages of CF lung disease, NET formation
may act beneficial in providing extracellular antibacterial and
antifungal host defense. At this time, DNasemay be usedwith
more caution, since encaptured pathogensmight be freed and
could cause additional host damage. On the other hand, in
latermoderate to severe stages of CF lung disease, the amount
of mucus and DNA accumulation causes airway obstruction,
rendering DNase efficient in cleaving DNA traps, and this
effect probably overweighs the antimicrobial actions of NET
formation, a hypothesis that awaits to be tested in further in
vivo studies and clinical trials. Our correlations between free
DNA levels and pulmonary obstruction parameters in human
patients with CF and a mouse model of CF lung disease
suggest that, at least in our CF cohort with a more advanced
lung disease severity, NETs may cause more harm than good
to the host. The obvious limitations of our study and the
whole approach of free DNA analysis in CF airway fluids
remain that the free extracellular DNA could result from
different forms of cell death in addition to NETosis, including
necrosis, pyroptosis, and others. In addition, our studies
image NET formation using fixation of biological samples
and are thereby limited by the fact that DNA structures
reminiscent of NETosis cannot be clearly attributed to active
NET formation, since this would require live cell imaging
approaches. Nevertheless, several other previous publications
have provided indirect evidence indicating the presence
of NET structures in CF airway fluids [10–14], which is
supported methodologically by our studies using confocal
laser scanning, scanning electron microscopy, transmission
electron microscopy, and atomic force microscopy, decreas-
ing the probability of fixation/staining artefacts.
As CF lung disease is typically associated with chronic
colonizations and infections with Pseudomonas aeruginosa,
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Figure 2: Free DNA, disease severity, and infection in CF lung disease. (a) Stratification of CF patients (𝑛 = 80). Upper left: correlation of
free DNA levels with FEV
1
in sputum supernatants from CF patients. Upper right: free DNA levels in sputum supernatants from healthy
controls and CF patients, stratified by FEV
1
. Lower panels: free DNA levels in sputum supernatants from healthy controls and CF patients,
stratified by Pseudomonas aeruginosa orAspergillus fumigatus infection/colonization status (Leeds criteria, 0: never, 1: negative, 2: intermittent,
and 3: chronic). (b) Representative CLSM images of airway fluids from one healthy individual and three different CF patients, stratified for
lung function, are depicted. Scale bar: 10𝜇m; FEV
1
: forced expiratory volume in 1 second (% of prediction). DAPI staining of nuclei and
extracellular DNA strands in CF sputa. (c) Chemokine levels in sputum supernatants from healthy controls (white, 𝑛 = 6) or CF patients
(grey, 𝑛 = 50). (d) Correlation of free DNA with CXCL2 levels in airway fluids (cell-free sputum supernatants) from CF patients (𝑛 = 50).
∗
𝑃 < 0.05.














































































Figure 3: Free DNA in murine CF lung disease in vivo. (a) CXCR2 chemokines in BALF from 𝛽ENaC-transgenic (𝛽ENaC-Tg, 𝑛 = 19) and
wild-type (WT, 𝑛 = 11) mice. Levels of CXCL1 (KC) and CXCL2 (MIP-2) were quantified by ELISA. (b) Free DNA in BALs from 𝛽ENaC-Tg
mice. Free DNA was quantified in BALF from 𝛽ENaC-Tg (filled circles, 𝑛 = 19) and wild-type (empty circles, 𝑛 = 11) mice. (c) Correlation
of free DNA with CXCL2 levels in BAL. (d) Correlation of free DNA with lung function (FEV100). ∗𝑃 < 0.05.
the effect of this pathogen on NET formation has been
investigated using different methodologies and modelling
systems [11, 13, 47–49]. The latter studies found that Pseu-
domonas aeruginosa efficiently induced NET formation,
particularly in solution in vitro, and demonstrated that
NETs can kill this pathogen through an extracellular DNA-
mediatedmechanism.At single cell level, authors also showed
that neutrophils from CF patients had no cell intrinsic
alteration in NET formation [11], supporting the notion
that the NET accumulation found in CF airway fluids is
not specific to CFTR mutation-based disease conditions,
but rather represent a prototypical picture of severe and
chronic neutrophilic inflammation in a body compartment.
Serum DNases and/or antioxidants have been shown to
dampen/inhibit NET formation. As CF airway fluids show
a low antioxidant activity and are substantially different in
their biochemical properties, we speculate that this particular
microenvironment favors NET formation. While we did not
find a statistically significant association of Pseudomonas
aeruginosa infection status with free DNA levels, a positive
correlationwas found for fungal colonizationwithAspergillus
fumigatus, which is in line with a recent study showing that
NETs are mainly formed in response to large pathogens, such
as fungi [50].
A recent study analyzing neutrophils from a patient with
Papillon-Lefevre syndrome (PLS), lacking serine proteases,
showed that neutrophils from this patient failed to produce
NETs [51], corroborating the concept that serine proteases,
particularly elastase, regulate NET formation [50, 52–54].
Papayannopoulos and coworkers demonstrated that neu-
trophil elastase, which is highly increased in CF airway fluids
and represents a promising therapeutic target [1, 4], enhances
sputum solubilization by cleaving histones to enhance the
access of exogenous nucleases to DNA [10]. The researchers
also showed that neutrophil elastase is bound to DNA, which
downregulates its proteolytic activity and could restrict host
tissue damage. This study has been extended by a recent
report demonstrating that NETs represent a reservoir of
active proteases and DNase treatment increases free pro-
teolytic activities [55], suggesting that CF patients under
DNase treatment could benefit from the addition of protease
inhibitors [56].
Previous studies found a correlation between airway
DNA levels, neutrophilic inflammation, and lung function
parameters in CF patients [9, 57, 58]. Our study confirms
and extends these findings by showing a correlation between
free DNA levels with lung function, chemokine levels, and
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fungal colonization in CF patients. The correlation between
the neutrophil chemokine CXCL2 and free DNA levels in CF
airway fluids could, on one hand, reflect increased CXCL2-
mediated neutrophil chemotaxis or could also, on the other
hand, involve CXCL2 itself as potential trigger for DNA
release in neutrophils. As there is a lack of convincing data
supporting the latter hypothesis, the underlying mechanistic
basis for this correlation remains to be dissected in the future.
Besides NET-associated products, such as proteases, that
can cause harm to the host, a recent study identified sur-
factant protein D as key protein binding to NETs, thereby
promotingNET-mediated trapping of P. aeruginosa [59].This
has ample implications for CF lung disease, since surfactant
protein D has been found to be degraded/cleaved by both
serine and matrix metalloproteases in CF airway fluids
[60–64], which, as a result, could impair the antibacterial
NETosis-related effects of surfactant protein D in CF airways
in vivo. Regarding surfactant protein D and beyond, proteins
that may interfere with NET formation and/or NET activities
could be attractive therapeutic targets for advanced CF lung
disease.
Our view of NET formation has been further extended
by the description of rapid NET formation in vitro [65] and
in vivo [24, 25], unraveling a so far unappreciated mode
of collaboration between NET formation, chemotaxis, and
phagocytosis.While there is convincing data in skin infection
models in mice, evidence on human neutrophils is still lim-
ited. The potential role of rapid NET formation for CF lung
disease remains to be dissected.
In summary, our study, in line with previous investiga-
tions, demonstrates that free DNA with NET-like character-
istics represents an extracellular component of CF airway
fluids. In advanced stages of CF lung disease, NETs seem
to do more harm than good, but experimental data for
a causative relationship is lacking. Approaches to interfere
with NET formation or NET-associated products, such as
DNases, antiproteases, supplementing surfactant protein D,
targeting histones [66], or a combination thereof, could
represent promising therapeutic strategies forCF lung disease
and other chronic lung diseases associated with sustained
neutrophilic inflammation [38, 40, 43].
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